Treat breast cancer patients sooner

Rapid test yields results in 10–14 days

When it comes to breast cancer treatment, recent studies have shown that a longer time to treatment completion has a negative impact on the overall outcome and survival of patients.1,2

Mayo Clinic Laboratories’ Rapid Breast Cancer Treatment Decision Panel (Mayo ID: BRTP) is designed to detect 11 genes that are linked to lifetime breast cancer risk, in alignment with guidelines established by the National Comprehensive Cancer Network (NCCN). With results delivered in 10–14 days, clinicians and patients will have the information they need to quickly guide treatment decisions.

Key testing

BRTP | Rapid Hereditary Breast Cancer Treatment Decision Panel, Varies

  • Uses next-generation sequencing to detect germline genetic alterations including sequence and copy number variants in 11 genes that have established associations with breast cancer.
  • Carefully designed to balance clinical utility diagnostic yields and future-proofing that will generate the most impactful genetic testing results for patients with breast cancer.

Breast cancer panel halves turnaround time

In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.

Learn more

Diagnosis and treatment options

Of the 11 genes our rapid breast cancer panel is designed to detect, seven are considered high risk based on National Comprehensive Cancer Network (NCCN) guidelines for breast cancer risk management and treatment.

The high-risk genes (BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53) carry a 40%–60% lifetime likelihood of the presence of cancer. NCCN guidelines also include recommendations regarding prophylactic surgeries for the seven high-risk genes. If any of the seven high-risk genes are detected, NCCN guidelines recommend starting mammograms or breast MRIs at a much younger age (potentially as young as 20 years old, depending on which gene is involved).

Our panel also includes four moderate-risk genes, allowing clinicians to cast a broader net and reduce the need for subsequent reflex testing. The four moderate-risk genes (ATM, CHEK2, RAD51C, and RAD51D) indicate a 20%–40% lifetime likelihood of cancer occurrence.

Learn more about how to order these evaluations at your institution.

References

  1. Pratt D, Burneikis T, Tu C, Grobmyer S. Time to completion of breast cancer treatment and survival. Ann Surg Oncol. 2021;28(13):8600-8608. doi:10.1245/s10434-021-10116-9.
  2. Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States [published correction appears in JAMA Oncol. 2016 Sep 1;2(9):1244]. JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508.